Project Grant R21AI200047
- The National Institute of General Medical Sciences awarded the University of Wisconsin – Madison $412,201 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate how metabolic microenvironments direct immune cell plasticity and function. The research project develops and applies an organotypic array for culture in live-cell environments (ORACLE), a micropatterned 3D hydrogel platform with functional vasculature that enables spatial and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $213,811 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop chimeric antigen receptor-engineered neutrophils as a therapeutic for Aspergillus fumigatus infection. The award funds research to engineer induced pluripotent stem cell-derived neutrophils armed with anti-Aspergillus CARs to overcome the limited efficacy of conventional antifungal agents...
- The National Institutes of Health Office of the Director awarded the University of Wisconsin - Madison $130,383 on July 15, 2026, under the Research Infrastructure Programs (CFDA 93.351) to conduct research on lymphatic regulation of neutrophil phenotypes in wound healing using a microphysiological approach with microbiome-based therapeutic insights. The research develops a physiologically relevant microphysiological system using LumenExt technology that mimics the wound microenvironment with...
- The National Institute of General Medical Sciences awarded the University of Wisconsin - Madison $413,001 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop computational systems for analyzing single-cell and spatial transcriptomics experiments. The recipient will create computational methods to improve downstream analysis of gene-expression data from single-cell and spatial transcriptomics experiments, which measure genome-wide expression in...
- The National Institute of General Medical Sciences awarded the University of Wisconsin–Madison $116,005 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support molecular research on neutrophil reverse migration in wound healing. The award funds the K99 phase of a study examining neutrophil subpopulations and their role in inflammation resolution. The research identifies key neutrophil subpopulations involved in reverse migration, tracks their...
- Federal Grant Award Summary The National Institutes of Health Office of the Director awarded University of Wisconsin–Madison a $1.49 million Project Grant under the Trans-NIH Research Support program (CFDA 93.310) on September 16, 2025, with a completion date of August 31, 2027. This research initiative focuses on developing and characterizing humanized mouse models to study Down syndrome immune responses, specifically addressing the immune dysregulation associated with trisomy 21. The project...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $233,250 on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate peptidoglycan fragment release by Neisseria gonorrhoeae and its role in inflammatory tissue damage during pelvic inflammatory disease. The research examines how N. gonorrhoeae releases peptidoglycan fragments that trigger damaging inflammatory responses, including ciliated cell death...
- The National Institute of General Medical Sciences awarded the University of Wisconsin – Madison $580,507 on May 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mechanisms governing midbody remnants in intercellular RNA communication. Over the five-year period of performance through February 28, 2031, the research will characterize the molecular cargo of midbody remnants—large extracellular vesicles released during cell division—across diverse...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $152,168 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental programming of hematopoietic stem and progenitor cells using an integrin A4 mutant zebrafish model. The research characterizes how hematopoietic stem and progenitor cells interact with their microenvironment during mammalian development. The award funds analysis of transcriptomic...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services National Institutes of Health, awarded $259,270 to the University of Wisconsin–Madison on August 20, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). This Project Grant (R01GM170992) supports development of data infrastructure, analytic methods, and forecasting models to measure how federally funded biomedical research translates into improved health...
The National Institutes of Health Office of the Director awarded $415,538 to the University of Wisconsin System, University of Wisconsin - Madison Division, on August 5, 2026, under the Trans-NIH Research Support program (CFDA 93.310), a Project Grant (R21AI200047). The award funds research on regulation of neutrophil heterogeneity and activation state using human induced pluripotent stem cell-derived neutrophils (iNeutrophils). The work employs single-cell multi-omics and imaging to understand how the transcription factor GATA1 and its isoforms modulate iNeutrophil development and function, with the long-term goal of engineering neutrophils with improved antimicrobial properties for human disease treatment. The recipient has previously engineered GMP-compatible human iNeutrophils with improved antimicrobial function and demonstrated that GATA1 depletion from human iPSCs results in a uniform mature iNeutrophil population with greater maturity and less heterogeneity. Performance occurs in Madison, Wisconsin. The period of performance runs through August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $415.5k | 9/3/26 | ||
| Not listed | ($227k) | 8/18/26 | ||
| Not listed | $227.3k | 8/5/26 |